Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus

D J Pettitt, P Ospina, C Howard, H Zisser, L Jovanovic, D J Pettitt, P Ospina, C Howard, H Zisser, L Jovanovic

Abstract

Aim: The efficacy and safety of insulin aspart (IAsp), a rapid-acting human insulin analogue, were compared with regular human insulin (HI) as the bolus component of basal-bolus therapy for subjects with gestational diabetes mellitus (GDM).

Methods: In a randomized, parallel-group, open-labelled trial, 27 women with GDM (age 30.7 +/- 6.3 years, HbA(1c) < 7%) were randomized to receive IAsp (5 min before meal) or HI (30 min before meal). The trial period extended from diagnosis of GDM (18-28 weeks) to 6 weeks postpartum.

Results: Both treatment groups maintained good overall glycaemic control during the study (beginning and end of study HbA(1c)< or = 6%). During the meal test, mean glucose at week 6 (IAsp 4.2 +/- 0.57 mmol/l, HI 4.8 +/- 0.86 mmol/l) was slightly lower than at week 0 (IAsp 4.9 +/- 0.59 mmol/l, HI 5.1 +/- 0.36 mmol/l). However, change from baseline values for average glucose (IAsp -1.09 +/- 0.54 mmol/l, HI -0.54 +/- 0.74 mmol/l; P = 0.003) and C-peptide (IAsp -0.50 +/- 0.67 nmol/l, HI -0.30 +/- 0.70 nmol/l; P = 0.027) were significantly lower after IAsp treatment than HI treatment. No major hypoglycaemic events were reported during the study. Cross-reacting insulin antibody binding increased slightly from baseline in both treatments groups (end of study: IAsp 2.1 +/- 5.4%, HI 6.4 +/- 13.9%), whereas antibodies specific to IAsp or HI remained relatively low (< 1% binding).

Conclusion: IAsp was more effective than HI in decreasing postprandial glucose concentrations. Duration of IAsp injection 5 min before a meal rather than 30 min prior to meals offers a more convenient therapy for subjects with GDM. Overall safety and effectiveness of IAsp were comparable to HI in pregnant women with GDM.

Figures

FIGURE 1
FIGURE 1
Average glucose profile during the meal tests. Average glucose (mmol/l) concentrations during the 4-h meal test with insulin aspart (IAsp) or regular insulin (HI). ▵, HI; ▪, IAsp.

References

    1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:S5–S20.
    1. American Diabetes Association Gestational diabetes mellitus (Position Statement) Diabetes Care. 2004;27:S88–S90.
    1. Metzger BE, Coustan DM. Organizing Committee: Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 1998;21:B161–B167.
    1. O'Sullivan JB. Diabetes mellitus after GDM. Diabetes. 1991;29:131–135.
    1. Pallardo F, Herranz L, Garcia-Ingelmo T, Grande C, Martin-Vaquero P, Janez M, et al. Early postpartum metabolic assessment in women with prior gestational diabetes. Diabetes Care. 1999;22:1053–1058.
    1. Langer O, Mazze R. The relationship between large-for-gestational-age infants and glycemic control in women with gestational diabetes. Am J Obstet Gynecol. 1988;159:1478–1483.
    1. Persson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus. Diabetes Care. 1998;21:B79–B84.
    1. Jovanovic L, Crues J, Durak E, Peterson CM. Magnetic resonance imaging in pregnancies complicated by diabetes predicts infant birth weight ratio and neonatal morbidity. Am J Perinatol. 1993;10:432–437.
    1. Hollingsworth DR, Cousins L. Endocrine and metabolic disorders. In: Creasy RK, Resnik E, editors. Maternal fetal medicine: principles and practice. Philadelphia: W.B. Saunders Co; 1984. pp. 833–896.
    1. American Diabetes Association Gestational diabetes mellitus. Diabetes Care. 2000;21:S77–S79.
    1. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768–773.
    1. Jovanovic L, Petersen CM, Reed GF, Metzger BE, Mills JL, Knopp RH, et al. Maternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study. Am J Obstet Gynecol. 1991;164:103–111.
    1. Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care. 1992;15:1251–1257.
    1. Jovanovic-Peterson L, Peterson CM. Rationale for prevention and treatment of glucose-mediated macrosomia: a protocol for gestational diabetes. Endocrine Prac. 1996;2:118–129.
    1. Menon RK, Cohen RM, Sperling MA, Cutfield WS, Mimouni F, Khoury JC. Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus: its role in fetal macrosomia. N Engl J Med. 1990;323:309–315.
    1. Jovanovic L, Sanja I, Pettitt DJ, Hugo K, Gutierrez M, Bowsher RR, Bastyr EJ. The metabolic and immunologic effect of insulin lispro in gestational diabetes. Diabetes Care. 1999;22:1422–1427.
    1. Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003;26:183–186.
    1. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23:583–588.
    1. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes. 1996;45:1750–1754.
    1. Ottesen J, Nilsson P, Jami J, Weilguny D, Durhrkop M, Bucchini D, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia. 1994;37:1178–1185.
    1. Chow SC, Liu JF. Design and Analysis of Bioavailability and Bioequivalence Study Design. 2. New York: Marcel Dekker; 2000. p. 8.
    1. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22:801–805.
    1. Perriello G, Avogaro A, Bosi E. Novo Nordisk Book of Abstracts. San Francisco, CA: American Diabetes Association 62nd Scientific Sessions; Superior meal-time glucose control with insulin aspart (NovoLog) compared with human insulin in both normal-weight and overweight people with type 2 diabetes—a randomized, stratified, double-blind, crossover trial; pp. 14–18.
    1. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41–46.
    1. Jovanovic L, Peterson CM, Reed GF, Metzger BE, Mills JL, Knopp RH, Aarons JH. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. Am J Obstet Gynecol. 1991;164:103–111.
    1. Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care. 1992;15:1251–1257.
    1. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus pre-prandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237–1241.
    1. Setter SM, Corbett CF, Campbell RK, White JR. Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother. 2000;34:1423–1431.
    1. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care. 2003;26:1390–1394.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner